aspartic acid has been researched along with Neoplasms in 115 studies
Aspartic Acid: One of the non-essential amino acids commonly occurring in the L-form. It is found in animals and plants, especially in sugar cane and sugar beets. It may be a neurotransmitter.
aspartic acid : An alpha-amino acid that consists of succinic acid bearing a single alpha-amino substituent
L-aspartic acid : The L-enantiomer of aspartic acid.
Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In vivo magnetic resonance spectroscopy (MRS) studies of glial brain tumours reported that higher grade of astrocytoma is associated with increased level of choline-containing compounds (Cho) and decreased levels of N-acetylaspartate (NAA) and creatine and phosphocreatine (Cr)." | 3.73 | In vitro study of astrocytic tumour metabolism by proton magnetic resonance spectroscopy. ( Belan, V; Béres, A; De Riggo, J; Dobrota, D; Galanda, M; Likavcanová, K; Liptaj, T; Mlynárik, V; Prónayová, N, 2005) |
| "In a previous trial in which methotrexate and N-phosphonacetyl-L-aspartate (PALA) were used to modulate 5-fluorouracil (5-FU), four of six patients could not tolerate treatment at the 600 mg/m2 5-FU dose level because of mucositis, diarrhea, and a decrease in performance status." | 3.68 | Uridine allows dose escalation of 5-fluorouracil when given with N-phosphonacetyl-L-aspartate, methotrexate, and leucovorin. ( Colofiore, J; Kemeny, N; Martin, D; Sawyer, R; Schneider, A; Seiter, K; Williams, L, 1993) |
| "We examine the implications of αVβ6 in cancer progression and the promotion of epithelial-mesenchymal transition (EMT) by contributing to the activation of transforming growth factor beta TGF-β." | 2.82 | Integrin Alpha v Beta 6 (αvβ6) and Its Implications in Cancer Treatment. ( Brzozowska, E; Deshmukh, S, 2022) |
| "Diarrhea was dose-limiting; 6/13 patients had grade II or worse diarrhea at 2,600 mg/m2." | 2.68 | Phase I study of phosphonacetyl-L-aspartate, 5-fluorouracil, and leucovorin in patients with advanced cancer. ( Brennan, J; Hageboutros, A; Hudes, GR; LaCreta, FP; McAleer, C; Newman, EM; O'Dwyer, PJ; Ozols, RF; Rogatko, A, 1995) |
| "Eighty-eight patients with advanced cancer were entered into this Phase I trial." | 2.68 | Phase I study of N-(phosphonacetyl)-L-aspartate with fluorouracil and with or without dipyridamole in patients with advanced cancer. ( Capizzi, RL; Case, L; Fernandes, DJ; Fleming, RA; Homesley, H; Loggie, BW; Morris, R; Muss, HB; Richards, F; Russell, GB; Smith, S, 1996) |
| "Four of ten patients with colorectal cancer responded to the treatment (four partial responses), of whom three had been treated previously." | 2.67 | A phase I, II study of high-dose 5-fluorouracil and high-dose leucovorin with low-dose phosphonacetyl-L-aspartic acid in patients with advanced malignancies. ( Ardalan, B; Benedetto, P; Feun, L; Fodor, M; Livingstone, A; Morrell, L; Richman, S; Savaraj, N; Sridhar, KS; Waldman, S, 1991) |
| " The main outcome was adverse events [all-cause mortality, cancers, rhabdomylosis, diabetes, aspartate and alanine aminotransferase (AST/ALT), and creatinine kinase (CK) increases beyond the upper limit of normal]." | 2.48 | Adverse events associated with individual statin treatments for cardiovascular disease: an indirect comparison meta-analysis. ( Alberton, M; Briel, M; Druyts, E; Mills, EJ; Wu, P, 2012) |
| "l-Aspartic acid was chosen and different amide-side chain-functionalized di-ester monomers were tailor-made having aromatic, aliphatic, and bio-source pendant units." | 1.91 | Melt Polycondensation Strategy for Amide-Functionalized l-Aspartic Acid Amphiphilic Polyester Nano-assemblies and Enzyme-Responsive Drug Delivery in Cancer Cells. ( Jayakannan, M; Khuddus, M, 2023) |
| "Aspartic acid is a non-essential amino acid obtained in the neuroendocrine tissues of vertebrates and invertebrates." | 1.91 | Differential detection of aspartic acid in MCF-7 breast cancer cells. ( Chattopadhyay, A; Das, T; Ghosh, P; Sahoo, P, 2023) |
| " Here, we present an extensively characterized series of potent, orally bioavailable inhibitors of the class I glucose transporters (GLUTs)." | 1.72 | Inhibition of glucose transport synergizes with chemical or genetic disruption of mitochondrial metabolism and suppresses TCA cycle-deficient tumors. ( Barsotti, A; Feng, XJ; Gaffney, J; Kim, JI; Lamarque, C; Liu, KG; Momcilovic, M; Morris, K; Olszewski, K; Patel, JP; Poyurovsky, MV; Rabinowitz, JD; Shackelford, DB; Yu, X, 2022) |
| "Even in sensitive cancer cells, though, biguanide treatment alone over a broad range of doses only inhibits cell replication without significantly affecting cell viability." | 1.62 | Biguanide drugs enhance cytotoxic effects of cisplatin by depleting aspartate and NAD+ in sensitive cancer cells. ( Bharti, S; Bhujwalla, Z; Gabrielson, E; Tully, E; Woo, J, 2021) |
| "Cellular aspartate drives cancer cell proliferation, but signaling pathways that rewire aspartate biosynthesis to control cell growth remain largely unknown." | 1.51 | HIF1α Suppresses Tumor Cell Proliferation through Inhibition of Aspartate Biosynthesis. ( Acker, T; Aragonés, J; Böğürcü-Seidel, N; Bouthelier, A; De Bock, K; Elorza, A; Escasany, E; Fendt, SM; Fraga, E; Fuertes, E; Giménez-Bachs, JM; Hernansanz-Agustín, P; Li, QOY; Lorendeau, D; Martínez-Ruiz, A; Meléndez-Rodríguez, F; Mesa-Ciller, C; Ortega Muelas, M; Pérez, B; Rinaldi, G; Roche, O; Salinas-Sánchez, AS; Sánchez Prieto, R; Tello, D; Torres-Capelli, M; Turiel, G; Urrutia, AA, 2019) |
| "Numerous types of cancer also depend on asparagine for cell proliferation." | 1.46 | A Critical Role of Glutamine and Asparagine γ-Nitrogen in Nucleotide Biosynthesis in Cancer Cells Hijacked by an Oncogenic Virus. ( Eoh, H; Gao, SJ; Jung, JU; Lee, JJ; Li, T; Lu, C; Ramos da Silva, S; Zhu, Y, 2017) |
| "Although aberrant metabolism in tumors has been well described, the identification of cancer subsets with particular metabolic vulnerabilities has remained challenging." | 1.43 | Differential Aspartate Usage Identifies a Subset of Cancer Cells Particularly Dependent on OGDH. ( Allen, EL; Artin, E; Chen, Y; Choe, S; Cianchetta, G; Clasquin, MF; Coco, J; Dorsch, M; Fan, ZP; Huang, L; Jin, S; Mahoney, CE; Murtie, J; Pirman, D; Ren, J; Si, Y; Smolen, GA; Ulanet, DB, 2016) |
| "This suggests that cancer drug sensitivity and resistance are not intrinsic properties of cancer cells, and demonstrates that the environment can dictate sensitivity to therapies that impact cell metabolism." | 1.43 | Environment Dictates Dependence on Mitochondrial Complex I for NAD+ and Aspartate Production and Determines Cancer Cell Sensitivity to Metformin. ( Bush, LN; Davidson, SM; Freinkman, E; Gitego, N; Gui, DY; Hosios, AM; Luengo, A; Sullivan, LB; Thomas, CJ; Vander Heiden, MG, 2016) |
| "Compared with the healthy group, lung cancer, cervical cancer, breast cancer and gastric cancer patients with abnormal Savda had lower concentration of plasma amino acids except some amino acids." | 1.40 | [Plasma amino acid profiling of "same symptom for different disease" in Uyghur medicine based on high-performance liquid chromatography]. ( Eli, M; Kong, B; Mamtimin, B; Turahun, A; Upur, H, 2014) |
| "However, the great majority of human cancers undergo disruption of the p53-network." | 1.39 | N-(phosphonacetyl)-L-aspartate induces TAp73-dependent apoptosis by modulating multiple Bcl-2 proteins: potential for cancer therapy. ( Agarwal, MK; Agarwal, ML; Gupta, K; Ruhul Amin, AR; Shin, DM; Thakur, VS; Wald, DN, 2013) |
| "Hyperthermia plays an important role in cancer therapy." | 1.38 | Heat induces gene amplification in cancer cells. ( Dewhirst, M; Huang, C; Li, C; Liu, F; Neill, D; Ouyang, R; Yan, B, 2012) |
| "Delirium is associated with a host of negative outcomes, including increased risk of mortality, longer hospital stay, and poor long-term cognitive function." | 1.37 | Proton Magnetic Resonance Spectroscopy in adult cancer patients with delirium. ( Beglinger, LJ; Capizzano, AA; Gingrich, R; Magnotta, VA; Mills, JA; Vik, SM; Weckmann, MT; Yager, JR, 2011) |
| "Effect of ROS on angiogenesis in tumors expressing hot-spot p53 mutants was correlated with their ability to increase a content of HIF1 transcriptional factor responsible for up-regulation of VEGF-A mRNAs." | 1.35 | p53 hot-spot mutants increase tumor vascularization via ROS-mediated activation of the HIF1/VEGF-A pathway. ( Agapova, LS; Khromova, NV; Kopnin, BP; Kopnin, PB; Stepanova, EV, 2009) |
| "Recently, four cancer-associated mutants of the A-alpha subunit have been described: Glu64-->Asp in lung carcinoma, Glu64-->Gly in breast carcinoma, Arg418-->Trp in melanoma, and Delta171 - 589 in breast carcinoma." | 1.31 | Disruption of protein phosphatase 2A subunit interaction in human cancers with mutations in the A alpha subunit gene. ( Pham, HT; Ruediger, R; Walter, G, 2001) |
| "Twenty-one paired pharmacokinetic studies were completed on patients with colorectal, gastric, and hepatocellular cancer, utilizing positron emission tomography (PET), which allowed the acquisition of tumor, normal tissue, and plasma pharmacokinetic data and tumor blood flow (TBF) measurements." | 1.30 | Tumor, normal tissue, and plasma pharmacokinetic studies of fluorouracil biomodulation with N-phosphonacetyl-L-aspartate, folinic acid, and interferon alfa. ( Brady, F; Brown, G; Harte, RJ; Jones, T; Luthra, SJ; Matthews, JC; O'Reilly, SM; Osman, S; Price, PM; Tilsley, DW, 1999) |
| "VX2 (squamous cell carcinoma) tumor-bearing rabbits were injected with 50 micromol/kg ATN-4T intravenously and T1 -weighted images were recorded continuously." | 1.30 | Tumor-enhancement effect of a Mn3+ metalloporphyrin derivative (ATN-4T) in magnetic resonance imaging. ( Hayashi, T; Kobayashi, M; Kuroki, M; Sakata, I; Tajiri, H, 1999) |
| "We have analyzed several sets of tumors and normal control tissues for the presence of D-aspartate (D-Asp) and D-glutamate (D-Glu)." | 1.29 | Presence of D-aspartate and D-glutamate in tumor proteins. ( Bergljung, C; Bruna, J; Cerwinski, S; Chou, SJ; Fisher, GH; Gruneiro, A; Man, EH; Martin, T; Pappatheodorou, S; Torres, D, 1995) |
| "Fifteen patients with advanced solid tumors participated in a phase I study of a biochemically designed combination chemotherapy program which employed PALA and thymidine (TdR) with 5-FU." | 1.27 | Phase I evaluation of a biochemically designed combination: PALA, thymidine, and 5-FU. ( Casper, ES; Kemeny, N; Martin, DS; Michaelson, RA; Young, CW, 1984) |
| "It was found that SV40-induced hamster tumors, BHK21/cl 13 cells in culture, certain carcinogen-induced tumors in the Ehrlich ascites tumor, and a number of human carcinomas and adenocarcinomas contained a distinct increase (3- to 20-fold) in the percentage of a late-eluting aspartyl-tRNA over that found in nonmalignant tissues, other animal tumors, and in human melanomas and sarcomas." | 1.25 | The distribution and properties of aspartyl transfer RNA in human and animal tumors. ( Bowen, JM; Briscoe, WT; Griffin, AC; McBride, C, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 44 (38.26) | 18.7374 |
| 1990's | 19 (16.52) | 18.2507 |
| 2000's | 17 (14.78) | 29.6817 |
| 2010's | 22 (19.13) | 24.3611 |
| 2020's | 13 (11.30) | 2.80 |
| Authors | Studies |
|---|---|
| Diamandis, P | 1 |
| Wildenhain, J | 1 |
| Clarke, ID | 1 |
| Sacher, AG | 1 |
| Graham, J | 1 |
| Bellows, DS | 1 |
| Ling, EK | 1 |
| Ward, RJ | 1 |
| Jamieson, LG | 1 |
| Tyers, M | 1 |
| Dirks, PB | 1 |
| Olszewski, K | 1 |
| Barsotti, A | 1 |
| Feng, XJ | 1 |
| Momcilovic, M | 2 |
| Liu, KG | 1 |
| Kim, JI | 1 |
| Morris, K | 1 |
| Lamarque, C | 1 |
| Gaffney, J | 1 |
| Yu, X | 1 |
| Patel, JP | 1 |
| Rabinowitz, JD | 1 |
| Shackelford, DB | 2 |
| Poyurovsky, MV | 1 |
| Tully, E | 1 |
| Bharti, S | 1 |
| Woo, J | 1 |
| Bhujwalla, Z | 1 |
| Gabrielson, E | 1 |
| Song, Q | 1 |
| Yang, W | 1 |
| Deng, X | 1 |
| Zhang, Y | 5 |
| Li, J | 1 |
| Xing, X | 1 |
| Chen, W | 1 |
| Liu, W | 1 |
| Hu, H | 1 |
| Brzozowska, E | 1 |
| Deshmukh, S | 1 |
| Khuddus, M | 1 |
| Jayakannan, M | 1 |
| Allard, D | 1 |
| Cousineau, I | 1 |
| Ma, EH | 1 |
| Allard, B | 1 |
| Bareche, Y | 1 |
| Fleury, H | 1 |
| Stagg, J | 1 |
| Ghosh, P | 1 |
| Das, T | 1 |
| Chattopadhyay, A | 1 |
| Sahoo, P | 1 |
| Zhang, Z | 2 |
| Xia, S | 1 |
| Kong, Q | 1 |
| Li, S | 2 |
| Liu, X | 2 |
| Junqueira, C | 1 |
| Meza-Sosa, KF | 1 |
| Mok, TMY | 1 |
| Ansara, J | 1 |
| Sengupta, S | 1 |
| Yao, Y | 1 |
| Wu, H | 1 |
| Lieberman, J | 1 |
| Gubina, N | 1 |
| Leboeuf, D | 1 |
| Piatkov, K | 1 |
| Pyatkov, M | 1 |
| Ma, Y | 1 |
| Zhu, Q | 1 |
| Liang, J | 1 |
| Li, Y | 2 |
| Li, M | 1 |
| Wang, X | 1 |
| Zeng, Y | 1 |
| Jiao, Y | 1 |
| Duan, R | 1 |
| Xu, Y | 1 |
| Zeng, X | 1 |
| Xu, J | 1 |
| Liang, L | 1 |
| Wang, Z | 1 |
| Jiang, X | 1 |
| Xing, B | 1 |
| Liu, B | 1 |
| All, A | 1 |
| Li, X | 1 |
| Lee, LP | 1 |
| Li, Q | 1 |
| Fu, D | 1 |
| Zhang, J | 1 |
| Li, T | 2 |
| Wang, H | 2 |
| Hou, W | 1 |
| Niu, B | 1 |
| Guo, R | 1 |
| Liu, Y | 3 |
| Krall, AS | 1 |
| Mullen, PJ | 1 |
| Surjono, F | 1 |
| Schmid, EW | 1 |
| Halbrook, CJ | 1 |
| Thambundit, A | 1 |
| Mittelman, SD | 1 |
| Lyssiotis, CA | 1 |
| Knott, SRV | 1 |
| Christofk, HR | 1 |
| Han, X | 1 |
| Zhong, Y | 1 |
| Zhou, G | 1 |
| Qi, H | 1 |
| Ding, Q | 1 |
| Liu, Z | 1 |
| Song, Y | 1 |
| Qiao, X | 1 |
| Zhu, Y | 1 |
| Ramos da Silva, S | 1 |
| Lee, JJ | 1 |
| Lu, C | 1 |
| Eoh, H | 1 |
| Jung, JU | 1 |
| Gao, SJ | 1 |
| Fu, A | 1 |
| Danial, NN | 1 |
| Sullivan, LB | 2 |
| Luengo, A | 3 |
| Danai, LV | 1 |
| Bush, LN | 2 |
| Diehl, FF | 1 |
| Hosios, AM | 2 |
| Lau, AN | 2 |
| Elmiligy, S | 1 |
| Malstrom, S | 1 |
| Lewis, CA | 3 |
| Vander Heiden, MG | 3 |
| Garcia-Bermudez, J | 1 |
| Baudrier, L | 1 |
| La, K | 1 |
| Zhu, XG | 1 |
| Fidelin, J | 1 |
| Sviderskiy, VO | 1 |
| Papagiannakopoulos, T | 1 |
| Molina, H | 1 |
| Snuderl, M | 1 |
| Possemato, RL | 1 |
| Birsoy, K | 1 |
| Alkan, HF | 1 |
| Walter, KE | 1 |
| Madreiter-Sokolowski, CT | 1 |
| Stryeck, S | 1 |
| Al-Zoughbi, W | 1 |
| Thomas, CJ | 2 |
| Hoefler, G | 1 |
| Graier, WF | 1 |
| Madl, T | 1 |
| Bogner-Strauss, JG | 1 |
| Terry, AR | 1 |
| Hay, N | 1 |
| Jin, P | 1 |
| Sha, R | 1 |
| Liu, L | 1 |
| Bian, Y | 1 |
| Qian, J | 2 |
| Lin, J | 1 |
| Ishimwe, N | 1 |
| Hu, Y | 2 |
| Zhang, W | 1 |
| Yin, S | 1 |
| Ren, L | 1 |
| Wen, LP | 1 |
| Li, Z | 1 |
| Guo, T | 1 |
| Qiu, Y | 1 |
| Chen, X | 1 |
| Song, J | 1 |
| Yang, H | 1 |
| Meléndez-Rodríguez, F | 1 |
| Urrutia, AA | 1 |
| Lorendeau, D | 1 |
| Rinaldi, G | 1 |
| Roche, O | 1 |
| Böğürcü-Seidel, N | 1 |
| Ortega Muelas, M | 1 |
| Mesa-Ciller, C | 1 |
| Turiel, G | 1 |
| Bouthelier, A | 1 |
| Hernansanz-Agustín, P | 1 |
| Elorza, A | 1 |
| Escasany, E | 1 |
| Li, QOY | 1 |
| Torres-Capelli, M | 1 |
| Tello, D | 1 |
| Fuertes, E | 1 |
| Fraga, E | 1 |
| Martínez-Ruiz, A | 1 |
| Pérez, B | 1 |
| Giménez-Bachs, JM | 1 |
| Salinas-Sánchez, AS | 1 |
| Acker, T | 1 |
| Sánchez Prieto, R | 1 |
| Fendt, SM | 1 |
| De Bock, K | 1 |
| Aragonés, J | 1 |
| Mamtimin, B | 1 |
| Upur, H | 1 |
| Kong, B | 1 |
| Eli, M | 1 |
| Turahun, A | 1 |
| Bravo-Oro, A | 1 |
| Acosta-Yebra, D | 1 |
| Grimaldo-Zapata, IP | 1 |
| Reyes-Vaca, G | 1 |
| Huang, H | 1 |
| Yue, T | 1 |
| Xu, K | 1 |
| Golzarian, J | 1 |
| Yu, J | 1 |
| Huang, J | 2 |
| Rabinovich, S | 1 |
| Adler, L | 1 |
| Yizhak, K | 1 |
| Sarver, A | 1 |
| Silberman, A | 1 |
| Agron, S | 1 |
| Stettner, N | 1 |
| Sun, Q | 1 |
| Brandis, A | 1 |
| Helbling, D | 1 |
| Korman, S | 1 |
| Itzkovitz, S | 1 |
| Dimmock, D | 1 |
| Ulitsky, I | 1 |
| Nagamani, SC | 1 |
| Ruppin, E | 1 |
| Erez, A | 1 |
| Allen, EL | 1 |
| Ulanet, DB | 1 |
| Pirman, D | 1 |
| Mahoney, CE | 1 |
| Coco, J | 1 |
| Si, Y | 1 |
| Chen, Y | 1 |
| Huang, L | 1 |
| Ren, J | 1 |
| Choe, S | 1 |
| Clasquin, MF | 1 |
| Artin, E | 1 |
| Fan, ZP | 1 |
| Cianchetta, G | 1 |
| Murtie, J | 1 |
| Dorsch, M | 1 |
| Jin, S | 2 |
| Smolen, GA | 1 |
| Gui, DY | 1 |
| Gitego, N | 1 |
| Davidson, SM | 1 |
| Freinkman, E | 1 |
| Khromova, NV | 1 |
| Kopnin, PB | 1 |
| Stepanova, EV | 1 |
| Agapova, LS | 1 |
| Kopnin, BP | 1 |
| Meng, M | 1 |
| Chen, S | 1 |
| Lao, T | 1 |
| Liang, D | 1 |
| Sang, N | 1 |
| Feng, Z | 1 |
| Li, W | 1 |
| Xue, X | 1 |
| Geng, X | 1 |
| Wu, Y | 1 |
| Wu, Z | 1 |
| Yager, JR | 1 |
| Magnotta, VA | 1 |
| Mills, JA | 1 |
| Vik, SM | 1 |
| Weckmann, MT | 1 |
| Capizzano, AA | 1 |
| Gingrich, R | 1 |
| Beglinger, LJ | 1 |
| Alberton, M | 1 |
| Wu, P | 1 |
| Druyts, E | 1 |
| Briel, M | 1 |
| Mills, EJ | 1 |
| Ruhul Amin, AR | 1 |
| Thakur, VS | 1 |
| Gupta, K | 1 |
| Agarwal, MK | 1 |
| Wald, DN | 1 |
| Shin, DM | 1 |
| Agarwal, ML | 1 |
| Yan, B | 1 |
| Ouyang, R | 1 |
| Huang, C | 1 |
| Liu, F | 1 |
| Neill, D | 1 |
| Li, C | 2 |
| Dewhirst, M | 1 |
| Thompson, CB | 1 |
| Jinno, H | 1 |
| Saeki, M | 1 |
| Saito, Y | 1 |
| Tanaka-Kagawa, T | 1 |
| Hanioka, N | 1 |
| Sai, K | 1 |
| Kaniwa, N | 1 |
| Ando, M | 1 |
| Shirao, K | 1 |
| Minami, H | 1 |
| Ohtsu, A | 1 |
| Yoshida, T | 1 |
| Saijo, N | 1 |
| Ozawa, S | 1 |
| Sawada, J | 1 |
| Bivén, K | 1 |
| Erdal, H | 1 |
| Hägg, M | 1 |
| Ueno, T | 1 |
| Zhou, R | 1 |
| Lynch, M | 1 |
| Rowley, B | 1 |
| Wood, J | 1 |
| Zhang, C | 1 |
| Toi, M | 1 |
| Shoshan, MC | 1 |
| Linder, S | 1 |
| MIZUSHIMA, S | 1 |
| IZAKI, K | 1 |
| TAKAHASHI, H | 1 |
| SAKAGUCHI, KI | 1 |
| REITH, WS | 2 |
| MICKELSON, MN | 1 |
| FLIPPIN, RS | 1 |
| MATSUURA, K | 1 |
| IMADA, R | 1 |
| FUJII, K | 1 |
| PATTERSON, MK | 1 |
| ORR, GR | 1 |
| MCCOY, TA | 1 |
| MELONI, GA | 1 |
| GENTY, N | 1 |
| VENDRELY, R | 1 |
| RYAN, WL | 1 |
| LORINCZ, AB | 1 |
| CAMBRIA, A | 1 |
| LOMBARDO, N | 1 |
| GIUFFRIDA, AM | 1 |
| BENNETT, LL | 1 |
| SMITHERS, D | 1 |
| WARD, CT | 1 |
| ANDERSON, EP | 1 |
| YEN, CY | 1 |
| MANDEL, HG | 1 |
| SMITH, PK | 1 |
| NIEPER, H | 1 |
| SAHASRABUDHE, MB | 1 |
| APTE, BK | 1 |
| ABOOBAKER, VS | 1 |
| JAYARAMAN, R | 1 |
| Fujii, Y | 1 |
| Okuda, D | 1 |
| Fujimoto, Z | 1 |
| Horii, K | 1 |
| Morita, T | 1 |
| Mizuno, H | 1 |
| Zhang, GD | 1 |
| Harada, A | 1 |
| Nishiyama, N | 1 |
| Jiang, DL | 1 |
| Koyama, H | 1 |
| Aida, T | 1 |
| Kataoka, K | 2 |
| NICKELL, LG | 1 |
| KIT, S | 1 |
| GREENBERG, DM | 1 |
| Tome, ME | 1 |
| Briehl, MM | 1 |
| Lutz, NW | 1 |
| Raguin, O | 1 |
| Fournié-Zaluski, MC | 1 |
| Romieu, A | 1 |
| Pèlegrin, A | 1 |
| Chatelet, F | 1 |
| Pélaprat, D | 1 |
| Barbet, J | 1 |
| Roques, BP | 1 |
| Gruaz-Guyon, A | 1 |
| Taylor, JR | 1 |
| Brownlow, N | 1 |
| Domin, J | 1 |
| Dibb, NJ | 1 |
| Likavcanová, K | 1 |
| Dobrota, D | 1 |
| Liptaj, T | 1 |
| Prónayová, N | 1 |
| Mlynárik, V | 1 |
| Belan, V | 1 |
| Galanda, M | 1 |
| Béres, A | 1 |
| De Riggo, J | 1 |
| Xiong, XB | 1 |
| Mahmud, A | 1 |
| Uludağ, H | 1 |
| Lavasanifar, A | 1 |
| Kumagai, M | 1 |
| Imai, Y | 1 |
| Nakamura, T | 1 |
| Yamasaki, Y | 1 |
| Sekino, M | 1 |
| Ueno, S | 1 |
| Hanaoka, K | 1 |
| Kikuchi, K | 1 |
| Nagano, T | 1 |
| Kaneko, E | 1 |
| Shimokado, K | 1 |
| Mathew, R | 1 |
| Kongara, S | 1 |
| Beaudoin, B | 1 |
| Karp, CM | 1 |
| Bray, K | 1 |
| Degenhardt, K | 1 |
| Chen, G | 1 |
| White, E | 1 |
| Steffen-Smith, EA | 1 |
| Wolters, PL | 1 |
| Albert, PS | 1 |
| Baker, EH | 1 |
| Shimoda, KC | 1 |
| Barnett, AS | 1 |
| Warren, KE | 1 |
| Coleman, PS | 1 |
| Lavietes, BB | 1 |
| Kovacevic, Z | 1 |
| McGivan, JD | 1 |
| Pawlicki, M | 1 |
| Zuchowska-Vogelgesang, B | 1 |
| Ardalan, B | 3 |
| Jamin, D | 1 |
| Jayaram, HN | 1 |
| Presant, CA | 1 |
| Martin, DS | 6 |
| Stolfi, RL | 2 |
| Sawyer, RC | 2 |
| Spiegelman, S | 1 |
| Young, CW | 4 |
| Casper, ES | 2 |
| Michaelson, RA | 1 |
| Kemeny, N | 2 |
| Baillon, J | 1 |
| Guichard, M | 1 |
| Malaise, EP | 1 |
| Hervé, G | 1 |
| Erlichman, C | 2 |
| Donehower, RC | 1 |
| Speyer, JL | 1 |
| Klecker, R | 1 |
| Chabner, BA | 2 |
| Weiss, GR | 1 |
| Ervin, TJ | 2 |
| Meshad, MW | 1 |
| Schade, D | 1 |
| Branfman, AR | 2 |
| Bruni, RJ | 2 |
| Chadwick, M | 2 |
| Kufe, DW | 1 |
| Moore, EC | 2 |
| Friedman, J | 2 |
| Valdivieso, M | 2 |
| Plunkett, W | 1 |
| Marti, JR | 2 |
| Russ, J | 1 |
| Loo, TL | 2 |
| Leyva, A | 2 |
| Appel, H | 1 |
| Smith, P | 1 |
| Lankelma, J | 1 |
| Pinedo, HM | 2 |
| Stewart, D | 1 |
| Merrill, YN | 1 |
| Strong, JM | 2 |
| Gralla, RJ | 1 |
| Natale, RB | 1 |
| Yagoda, A | 1 |
| Valdez, BC | 1 |
| Henning, D | 1 |
| Le, TV | 1 |
| Busch, H | 1 |
| Tlsty, TD | 2 |
| White, A | 2 |
| Livanos, E | 2 |
| Sage, M | 2 |
| Roelofs, H | 2 |
| Briot, A | 2 |
| Poulose, B | 2 |
| Machover, D | 1 |
| Hageboutros, A | 2 |
| Rogatko, A | 1 |
| Newman, EM | 1 |
| McAleer, C | 1 |
| Brennan, J | 2 |
| LaCreta, FP | 3 |
| Hudes, GR | 3 |
| Ozols, RF | 3 |
| O'Dwyer, PJ | 5 |
| Jonczyk, P | 1 |
| Hall, I | 1 |
| Schaefer, D | 1 |
| Spikes, JD | 1 |
| Bommer, JC | 1 |
| Seiter, K | 1 |
| Martin, D | 1 |
| Schneider, A | 2 |
| Williams, L | 1 |
| Colofiore, J | 3 |
| Sawyer, R | 1 |
| Green, F | 1 |
| Hoffman, J | 2 |
| Fisher, GH | 1 |
| Torres, D | 1 |
| Bruna, J | 1 |
| Cerwinski, S | 1 |
| Martin, T | 1 |
| Bergljung, C | 1 |
| Gruneiro, A | 1 |
| Chou, SJ | 1 |
| Man, EH | 1 |
| Pappatheodorou, S | 1 |
| Fleming, RA | 1 |
| Capizzi, RL | 1 |
| Muss, HB | 1 |
| Smith, S | 1 |
| Fernandes, DJ | 1 |
| Homesley, H | 1 |
| Loggie, BW | 1 |
| Case, L | 1 |
| Morris, R | 1 |
| Russell, GB | 1 |
| Richards, F | 1 |
| Harte, RJ | 1 |
| Matthews, JC | 1 |
| O'Reilly, SM | 1 |
| Tilsley, DW | 1 |
| Osman, S | 1 |
| Brown, G | 1 |
| Luthra, SJ | 1 |
| Brady, F | 1 |
| Jones, T | 1 |
| Price, PM | 1 |
| Kobayashi, M | 1 |
| Tajiri, H | 1 |
| Hayashi, T | 1 |
| Kuroki, M | 1 |
| Sakata, I | 1 |
| Lavelle, F | 1 |
| Ruediger, R | 1 |
| Pham, HT | 1 |
| Walter, G | 1 |
| Tanaka, T | 1 |
| Nakajima, T | 1 |
| Wiernik, PH | 1 |
| McAvoy, LM | 1 |
| Cohen, MH | 1 |
| Levine, AS | 1 |
| Hubbard, SM | 1 |
| Briscoe, WT | 2 |
| Griffin, AC | 2 |
| McBride, C | 1 |
| Bowen, JM | 1 |
| Von Hoff, DD | 1 |
| Walczak, J | 1 |
| Comis, RL | 1 |
| Stridhar, K | 1 |
| Reddy, R | 1 |
| Benedetto, P | 2 |
| Richman, S | 2 |
| Waldman, S | 2 |
| Morrell, L | 2 |
| Feun, L | 2 |
| Savaraj, N | 2 |
| Livingstone, A | 2 |
| Sridhar, KS | 1 |
| Fodor, M | 1 |
| Kemeny, NE | 1 |
| Peters, GJ | 1 |
| Laurensse, E | 1 |
| King, SA | 1 |
| Hoth, DF | 1 |
| Leyland-Jones, B | 1 |
| Chan, TC | 2 |
| Markman, M | 2 |
| Cleary, S | 2 |
| Howell, SB | 2 |
| Hoffer, PB | 1 |
| Gottschalk, A | 1 |
| Bodansky, O | 1 |
| Schwartz, MK | 1 |
| Nisselbaum, JS | 1 |
| Taylor, W | 1 |
| Duff, R | 1 |
| Rapp, F | 1 |
| Kronberger, L | 2 |
| Fink, E | 2 |
| Daill, M | 1 |
| Schindler, R | 1 |
| Ohnuma, T | 1 |
| Holland, JF | 1 |
| Freeman, A | 1 |
| Sinks, LF | 1 |
| Chaudhuri, TK | 1 |
| Winchell, HS | 1 |
| Schmidt, CG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| This Preliminary Study Was Designed to Explore a New Biological Method for Nutritional Assessment by Measuring Oral Mucosal Epithelial Cell Apoptosis Rate and Guideline to Clinical Nutrition Support Therapy for Improving Clinical Outcome of Malnourished P[NCT02102659] | 167 participants (Anticipated) | Interventional | 2014-03-31 | Active, not recruiting | |||
| A Phase II Study of the Combination of Gemcitabine and Imatinib Mesylate in Pemetrexed-pretreated Patients With Malignant Pleural Mesothelioma[NCT02303899] | Phase 2 | 22 participants (Actual) | Interventional | 2014-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
16 reviews available for aspartic acid and Neoplasms
| Article | Year |
|---|---|
Integrin Alpha v Beta 6 (αvβ6) and Its Implications in Cancer Treatment.
Topics: Antigens, Neoplasm; Arginine; Aspartic Acid; Glycine; Humans; Integrin alphaV; Integrins; Neoplasms; | 2022 |
Fuelling cancer cells.
Topics: Asparagine; Aspartic Acid; Disease Progression; Female; Humans; Lactic Acid; Male; Neoplasms; Oxygen | 2019 |
[Reversible cortical atrophy secondary to anti-NMDA receptor antibody encephalitis].
Topics: Anti-N-Methyl-D-Aspartate Receptor Encephalitis; Anticonvulsants; Aphasia, Broca; Aspartic Acid; Atr | 2015 |
Adverse events associated with individual statin treatments for cardiovascular disease: an indirect comparison meta-analysis.
Topics: Adult; Aged; Alanine Transaminase; Aspartic Acid; Cardiovascular Diseases; Creatinine; Diabetes Mell | 2012 |
Talaporfin: LS 11, LS11, ME 2906, mono-L-aspartyl chlorin e6, NP e6, NPE 6, taporfin sodium.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Chemistry, Pharmaceutical; C | 2003 |
Membrane cholesterol, tumorigenesis, and the biochemical phenotype of neoplasia.
Topics: Acetates; Animals; Asparagine; Aspartic Acid; Biological Transport, Active; Cell Division; Cell Memb | 1981 |
Mitochondrial metabolism of glutamine and glutamate and its physiological significance.
Topics: Acidosis; Animals; Aspartate Aminotransferases; Aspartic Acid; Brain; Cells, Cultured; Energy Metabo | 1983 |
[New antineoplastic agents, their value and use].
Topics: Aminacrine; Antineoplastic Agents; Aspartic Acid; Cisplatin; Etoposide; Humans; Ifosfamide; Interfer | 1982 |
Genomic integrity and the genetics of cancer.
Topics: Adenovirus E1A Proteins; Adenoviruses, Human; Antimetabolites; Apoptosis; Aspartic Acid; Cell Cycle; | 1994 |
The pharmacologic modulation of 5-fluorouracil with folinic acid, methotrexate, trimetrexate, and n-phosphonacetyl-l-aspartic acid (PALA). Mechanisms of the interactions and clinical data.
Topics: Aspartic Acid; Drug Interactions; Fluorouracil; Humans; Leucovorin; Methotrexate; Neoplasms; Phospho | 1994 |
New mechanisms of gene amplification in drug resistance (the episome model).
Topics: Animals; Antineoplastic Agents; Aspartate Carbamoyltransferase; Aspartic Acid; ATP Binding Cassette | 1991 |
The role of low-dose PALA in biochemical modulation.
Topics: Animals; Antineoplastic Agents; Aspartic Acid; Clinical Trials as Topic; Dose-Response Relationship, | 1990 |
Role of thymidine in biochemical modulation: a review.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Aspartic A | 1987 |
Application of biochemical modulation with a therapeutically inactive modulating agent in clinical trials of cancer chemotherapy.
Topics: Animals; Aspartic Acid; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Therapy, Co | 1985 |
Tumor scanning agents.
Topics: Antibodies, Neoplasm; Aspartic Acid; Bismuth; Bleomycin; Carbon Radioisotopes; Carcinoembryonic Anti | 1974 |
Isozymes of aspartate aminotransferase in tissues and blood of man.
Topics: Acute Disease; Adult; Aging; Alpha-Globulins; Animals; Aspartate Aminotransferases; Aspartic Acid; B | 1966 |
8 trials available for aspartic acid and Neoplasms
| Article | Year |
|---|---|
Detection and characterization of neurotoxicity in cancer patients using proton MR spectroscopy.
Topics: Adolescent; Adult; Aspartic Acid; Child; Child, Preschool; Choline; Creatine; Female; Humans; Magnet | 2008 |
The pharmacologic modulation of 5-fluorouracil with folinic acid, methotrexate, trimetrexate, and n-phosphonacetyl-l-aspartic acid (PALA). Mechanisms of the interactions and clinical data.
Topics: Aspartic Acid; Drug Interactions; Fluorouracil; Humans; Leucovorin; Methotrexate; Neoplasms; Phospho | 1994 |
Phase I study of phosphonacetyl-L-aspartate, 5-fluorouracil, and leucovorin in patients with advanced cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Aspart | 1995 |
Phase I trial of fluorouracil modulation by N-phosphonacetyl-L-aspartate and 6-methylmercaptopurine ribonucleoside.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Aspartic Aci | 1996 |
Phase I study of N-(phosphonacetyl)-L-aspartate with fluorouracil and with or without dipyridamole in patients with advanced cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aspartate Carbamoylt | 1996 |
Phase I trial of fluorouracil modulation by N-phosphonacetyl-L-aspartate and 6-methylmercaptopurine riboside: optimization of 6-methylmercaptopurine riboside dose and schedule through biochemical analysis of sequential tumor biopsy specimens.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Biops | 1991 |
A phase I, II study of high-dose 5-fluorouracil and high-dose leucovorin with low-dose phosphonacetyl-L-aspartic acid in patients with advanced malignancies.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; B | 1991 |
Application of biochemical modulation with a therapeutically inactive modulating agent in clinical trials of cancer chemotherapy.
Topics: Animals; Aspartic Acid; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Therapy, Co | 1985 |
93 other studies available for aspartic acid and Neoplasms
| Article | Year |
|---|---|
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutic | 2007 |
Inhibition of glucose transport synergizes with chemical or genetic disruption of mitochondrial metabolism and suppresses TCA cycle-deficient tumors.
Topics: Aspartic Acid; Citric Acid Cycle; Glucose; Humans; Mitochondria; Neoplasms | 2022 |
Biguanide drugs enhance cytotoxic effects of cisplatin by depleting aspartate and NAD+ in sensitive cancer cells.
Topics: Antineoplastic Agents; Aspartic Acid; Cisplatin; Metformin; NAD; Neoplasms; Pharmaceutical Preparati | 2021 |
Platinum-based nanocomposites loaded with MTH1 inhibitor amplify oxidative damage for cancer therapy.
Topics: Arginine; Aspartic Acid; Catalase; Cell Line, Tumor; Glycine; Humans; Hydrogen Peroxide; Liposomes; | 2022 |
Melt Polycondensation Strategy for Amide-Functionalized l-Aspartic Acid Amphiphilic Polyester Nano-assemblies and Enzyme-Responsive Drug Delivery in Cancer Cells.
Topics: Amides; Animals; Antineoplastic Agents; Aspartic Acid; Doxorubicin; Drug Carriers; Drug Liberation; | 2023 |
The CD73 immune checkpoint promotes tumor cell metabolic fitness.
Topics: Animals; Aspartic Acid; Cell Line, Tumor; Humans; Mice; Neoplasms | 2023 |
Differential detection of aspartic acid in MCF-7 breast cancer cells.
Topics: Amino Acids; Animals; Aspartic Acid; Humans; Mammals; MCF-7 Cells; Neoplasms | 2023 |
Gasdermin E suppresses tumour growth by activating anti-tumour immunity.
Topics: Animals; Apoptosis; Aspartic Acid; Cell Line, Tumor; Female; Granzymes; Humans; Loss of Function Mut | 2020 |
Novel Apoptotic Mediators Identified by Conservation of Vertebrate Caspase Targets.
Topics: Animals; Apoptosis; Aspartic Acid; Caspases; Conserved Sequence; Humans; Hydrophobic and Hydrophilic | 2020 |
A CRISPR knockout negative screen reveals synergy between CDKs inhibitor and metformin in the treatment of human cancer in vitro and in vivo.
Topics: Animals; Aspartic Acid; CDC2 Protein Kinase; Citric Acid Cycle; CRISPR-Cas Systems; Cyclin-Dependent | 2020 |
Uncovering the Metabolic Origin of Aspartate for Tumor Growth Using an Integrated Molecular Deactivator.
Topics: Antineoplastic Agents; Aspartic Acid; Cell Proliferation; Glucose; Humans; Neoplasms; Tumor Microenv | 2021 |
Poly(aspartic acid)-based pH-responsive targeting co-delivery nanoparticles.
Topics: Aspartic Acid; Curcumin; Doxorubicin; Drug Delivery Systems; Humans; Hyaluronic Acid; Hydrogen-Ion C | 2021 |
Asparagine couples mitochondrial respiration to ATF4 activity and tumor growth.
Topics: Activating Transcription Factor 4; Animals; Asparagine; Aspartic Acid; Cell Line, Tumor; Cell Prolif | 2021 |
Synthesis and biological evaluation of N-(carbobenzyloxy)-l-phenylalanine and N-(carbobenzyloxy)-l-aspartic acid-β-benzyl ester derivatives as potent topoisomerase IIα inhibitors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Aspartic Acid; Cell Line, Tumor; DNA Topoisomerases, Type | 2017 |
A Critical Role of Glutamine and Asparagine γ-Nitrogen in Nucleotide Biosynthesis in Cancer Cells Hijacked by an Oncogenic Virus.
Topics: Asparagine; Aspartate Aminotransferases; Aspartic Acid; Cell Proliferation; Glutamate Dehydrogenase; | 2017 |
Grasping for aspartate in tumour metabolism.
Topics: Aspartic Acid; Humans; Neoplasms | 2018 |
Aspartate is an endogenous metabolic limitation for tumour growth.
Topics: Animals; Antineoplastic Agents; Asparaginase; Aspartic Acid; Cell Proliferation; Drug Resistance, Ne | 2018 |
Aspartate is a limiting metabolite for cancer cell proliferation under hypoxia and in tumours.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Aspartic Acid; Biological Transport; | 2018 |
Cytosolic Aspartate Availability Determines Cell Survival When Glutamine Is Limiting.
Topics: Amino Acid Transport Systems, Acidic; Animals; Antiporters; Aspartic Acid; Cell Line; Cell Prolifera | 2018 |
Blood Circulation-Prolonging Peptides for Engineered Nanoparticles Identified via Phage Display.
Topics: Amino Acid Sequence; Arginine; Aspartic Acid; Bacteriophage M13; Biological Transport; Cell Surface | 2019 |
A Highly Effective π-π Stacking Strategy To Modify Black Phosphorus with Aromatic Molecules for Cancer Theranostics.
Topics: Arginine; Aspartic Acid; Glycine; Humans; Nanocomposites; Neoplasms; Peptides; Phosphorus; Photother | 2019 |
HIF1α Suppresses Tumor Cell Proliferation through Inhibition of Aspartate Biosynthesis.
Topics: Adult; Aged; Aged, 80 and over; Aspartate Aminotransferase, Cytoplasmic; Aspartate Aminotransferase, | 2019 |
[Plasma amino acid profiling of "same symptom for different disease" in Uyghur medicine based on high-performance liquid chromatography].
Topics: Amino Acids; Arginine; Aspartic Acid; Chromatography, High Pressure Liquid; Cystine; Humans; Isoleuc | 2014 |
Fabrication and evaluation of tumor-targeted positive MRI contrast agent based on ultrasmall MnO nanoparticles.
Topics: Animals; Aspartic Acid; Biopolymers; Cell Line, Tumor; Cell Survival; Contrast Media; Humans; Magnet | 2015 |
Diversion of aspartate in ASS1-deficient tumours fosters de novo pyrimidine synthesis.
Topics: Animals; Argininosuccinate Synthase; Aspartate Carbamoyltransferase; Aspartic Acid; Calcium-Binding | 2015 |
Differential Aspartate Usage Identifies a Subset of Cancer Cells Particularly Dependent on OGDH.
Topics: Animals; Aspartic Acid; Cell Line, Tumor; Cell Respiration; Citric Acid Cycle; Enzyme Inhibitors; Ge | 2016 |
Environment Dictates Dependence on Mitochondrial Complex I for NAD+ and Aspartate Production and Determines Cancer Cell Sensitivity to Metformin.
Topics: Animals; Aspartic Acid; Cell Line, Tumor; Cell Proliferation; Electron Transport Complex I; Homeosta | 2016 |
p53 hot-spot mutants increase tumor vascularization via ROS-mediated activation of the HIF1/VEGF-A pathway.
Topics: Aspartic Acid; Genes, p53; HCT116 Cells; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Mutation | 2009 |
Nitrogen anabolism underlies the importance of glutaminolysis in proliferating cells.
Topics: Alanine; Ammonia; Aspartic Acid; Carbon; Cell Line, Tumor; Cell Proliferation; Energy Metabolism; Gl | 2010 |
A novel GAP460 biopolymer for use as a carrier in drug-delivery applications.
Topics: Animals; Antineoplastic Agents; Aspartic Acid; Cell Line, Tumor; Cisplatin; Drug Carriers; Female; H | 2011 |
Proton Magnetic Resonance Spectroscopy in adult cancer patients with delirium.
Topics: Adult; Aged; Aspartic Acid; Bone Marrow Transplantation; Choline; Delirium; Female; Humans; Magnetic | 2011 |
N-(phosphonacetyl)-L-aspartate induces TAp73-dependent apoptosis by modulating multiple Bcl-2 proteins: potential for cancer therapy.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Apoptosis Regulatory Proteins; Aspartic Acid; Bcl-2-Like | 2013 |
Heat induces gene amplification in cancer cells.
Topics: Acid Anhydride Hydrolases; Acylphosphatase; Aspartate Carbamoyltransferase; Aspartic Acid; Dihydroor | 2012 |
Cancer. DNA damage, deamidation, and death.
Topics: Antineoplastic Agents; Apoptosis; Asparagine; Aspartic Acid; bcl-X Protein; Cyclin-Dependent Kinase | 2002 |
Functional characterization of human UDP-glucuronosyltransferase 1A9 variant, D256N, found in Japanese cancer patients.
Topics: Amino Acid Substitution; Animals; Antineoplastic Agents; Asparagine; Aspartic Acid; Camptothecin; CO | 2003 |
A novel assay for discovery and characterization of pro-apoptotic drugs and for monitoring apoptosis in patient sera.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; Aspartic Acid; Caspases; Cell Line, Tumor; | 2003 |
The determination of D-glutamic and D-aspartic acids content of malignant tumors and normal tissues by means of new oxidase.
Topics: Aspartic Acid; D-Aspartic Acid; Glutamates; Humans; Neoplasms; Oxidoreductases | 1956 |
Incorporation of radioactive aspartic acid into the proteins and related fractions in mice bearing the Ehrlich ascites carcinoma.
Topics: Animals; Ascites; Aspartic Acid; Carcinoma; Mice; Neoplasms; Proteins; Radioactivity | 1956 |
Incorporation of radioactive aspartic acid into the proteins and related fractions in mice bearing the Ehrlich ascites carcinoma.
Topics: Animals; Ascites; Aspartic Acid; Carcinoma; Mice; Neoplasms; Proteins; Radioactivity | 1956 |
Incorporation of radioactive aspartic acid into the proteins and related fractions in mice bearing the Ehrlich ascites carcinoma.
Topics: Animals; Ascites; Aspartic Acid; Carcinoma; Mice; Neoplasms; Proteins; Radioactivity | 1956 |
Incorporation of radioactive aspartic acid into the proteins and related fractions in mice bearing the Ehrlich ascites carcinoma.
Topics: Animals; Ascites; Aspartic Acid; Carcinoma; Mice; Neoplasms; Proteins; Radioactivity | 1956 |
Effects of certain amino acid derivatives on microorganisms and sarcoma 180.
Topics: Amino Acids; Animals; Antineoplastic Agents; Arginine; Aspartic Acid; Lactobacillus; Neoplasms; Sarc | 1958 |
[L-ASPARTIC ACID K,MG SALTS FOR RADIATION SICKNESS].
Topics: Animals; Aspartic Acid; Female; Japan; Lung Neoplasms; Magnesium; Mice; Neoplasms; Potassium; Radiat | 1963 |
ASPARAGINE-C14 AND GLUTAMINE-C14 FROM ANIMAL CELL PROTEIN AND THEIR CHEMICAL DEGRADATION.
Topics: Animals; Asparagine; Aspartic Acid; Carbon Isotopes; Chromatography; Glutamine; Ion Exchange Resins; | 1963 |
[CONTRIBUTION TO THE STUDY OF RIBONUCLEOPROTEINS OF NORMAL AND NEOPLASTIC TISSUES].
Topics: Alanine; Arginine; Aspartic Acid; Chemical Phenomena; Chemistry; Glutamates; Glycine; Isoleucine; Le | 1963 |
FREE AMINO ACIDS OF HUMAN BREAST CANCER.
Topics: Amino Acids; Asparagine; Aspartic Acid; Breast Neoplasms; Chromatography; Citrulline; Glutamates; Gl | 1964 |
[INCORPORATION OF FORMATE-C14 IN THE BASES OF THE NUCLEIC ACIDS OF STICKER'S TUMOR IN VIVO AND IN VITRO].
Topics: Adenine; Aspartic Acid; Carbon Isotopes; DNA; DNA, Neoplasm; Dogs; Formates; Glucose; Glutamine; In | 1963 |
INHIBITION OF DNA SYNTHESIS IN MAMMALIAN CELLS BY ACTIDIONE.
Topics: Adenine; Adenine Nucleotides; Anti-Bacterial Agents; Aspartic Acid; Carbon Isotopes; Carcinoma, Squa | 1964 |
Ureidosuccinic acid as a precursor of nucleic acid pyrimidines in normal and tumor-bearing mice.
Topics: Animals; Aspartic Acid; Mice; Neoplasms; Nucleic Acids; Pyrimidines | 1955 |
[Bases of experimentation and clinical applications of ion transporting agents. The normalizing action of the aspartates of K and Mg on the level of atypical substrates observed in cancer patients, and its significance in the problem of the condition of t
Topics: Aspartic Acid; Ion Transport; Magnesium; Neoplasms; Nutrition Therapy; Potassium; Research Design | 1961 |
Partial deletion of aspartic acid from DNA-proteins during butter yellow carcinogenesis.
Topics: Aspartic Acid; Carcinogenesis; Carcinogens; DNA; Liver; Liver Neoplasms; Neoplasms; Nucleoproteins; | 1962 |
Crystal structure of trimestatin, a disintegrin containing a cell adhesion recognition motif RGD.
Topics: Amino Acid Motifs; Amino Acid Sequence; Angiogenesis Inhibitors; Antineoplastic Agents; Asparagine; | 2003 |
Polyion complex micelles entrapping cationic dendrimer porphyrin: effective photosensitizer for photodynamic therapy of cancer.
Topics: Animals; Aspartic Acid; Carcinoma, Lewis Lung; Drug Carriers; Forecasting; Macromolecular Substances | 2003 |
Effect of aspartic acid on growth of plant-virus tumour tissue.
Topics: Aspartic Acid; Neoplasms; Physiological Phenomena | 1950 |
Tracer studies on the metabolism of the Gardner lymphosarcoma. IV. The conversion of lactate-2-C14 to alanine, glutamate, and aspartate by tumor and spleen cells.
Topics: Alanine; Aspartic Acid; Glutamates; Glutamic Acid; Lactic Acid; Lymphoma; Lymphoma, Non-Hodgkin; Neo | 1951 |
Increasing the antioxidant defense in WEHI7.2 cells results in a more tumor-like metabolic profile.
Topics: Adenosine Triphosphate; Amino Acids; Animals; Antioxidants; Aspartic Acid; Cell Line, Tumor; Glycoly | 2005 |
A labeled neutral endopeptidase inhibitor as a potential tool for tumor diagnosis and prognosis.
Topics: Animals; Aspartic Acid; Binding Sites; Binding, Competitive; Cell Line, Tumor; Humans; Mice; Mice, I | 2005 |
FMS receptor for M-CSF (CSF-1) is sensitive to the kinase inhibitor imatinib and mutation of Asp-802 to Val confers resistance.
Topics: Animals; Antineoplastic Agents; Aspartic Acid; Benzamides; Disease Progression; Dose-Response Relati | 2006 |
In vitro study of astrocytic tumour metabolism by proton magnetic resonance spectroscopy.
Topics: Aspartic Acid; Astrocytes; Astrocytoma; Brain; Brain Neoplasms; Choline; Chromium; Creatine; Gliobla | 2005 |
Conjugation of arginine-glycine-aspartic acid peptides to poly(ethylene oxide)-b-poly(epsilon-caprolactone) micelles for enhanced intracellular drug delivery to metastatic tumor cells.
Topics: Aldehydes; Arginine; Aspartic Acid; Cell Line, Tumor; Drug Delivery Systems; Glycine; Humans; Lacton | 2007 |
Iron hydroxide nanoparticles coated with poly(ethylene glycol)-poly(aspartic acid) block copolymer as novel magnetic resonance contrast agents for in vivo cancer imaging.
Topics: Animals; Aspartic Acid; Coated Materials, Biocompatible; Colonic Neoplasms; Contrast Media; Female; | 2007 |
Autophagy suppresses tumor progression by limiting chromosomal instability.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Aspartic Acid; Autophagy; Autophagy-Related Prote | 2007 |
Phase I study of continuous-infusion PALA and 5-FU.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartate Carbamoyltransferase; Asparti | 1984 |
Improved therapeutic index with sequential N-phosphonacetyl-L-aspartate plus high-dose methotrexate plus high-dose 5-fluorouracil and appropriate rescue.
Topics: Animals; Antineoplastic Agents; Aspartic Acid; Drug Therapy, Combination; Female; Fluorouracil; Leuc | 1983 |
Phase I evaluation of a biochemically designed combination: PALA, thymidine, and 5-FU.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Drug Evaluation; Fluorouracil; Humans | 1984 |
Kinetic parameters of aspartate transcarbamylase in human normal and tumoral cell lines.
Topics: Aspartate Carbamoyltransferase; Aspartic Acid; Cell Count; Cell Extracts; Cell Line; Cell-Free Syste | 1983 |
Phase I-phase II trial of N-phosphonacetyl-L-aspartic acid given by intravenous infusion and 5-fluorouracil given by bolus injection.
Topics: Adult; Aged; Antineoplastic Agents; Aspartic Acid; Colonic Neoplasms; Drug Administration Schedule; | 1982 |
A phase I trial of combination therapy with continuous-infusion PALA and continuous-infusion 5-FU.
Topics: Adult; Aged; Antineoplastic Agents; Aspartic Acid; Bone Marrow; Digestive System; Drug Evaluation; D | 1982 |
Aspartate carbamoyltransferase activity, drug concentrations, and pyrimidine nucleotides in tissue from patients treated with N-(phosphonacetyl)-L-aspartate.
Topics: Antimetabolites, Antineoplastic; Aspartate Carbamoyltransferase; Aspartic Acid; Drug Evaluation; Hum | 1982 |
Inhibition of cell growth by N-(phosphonacetyl)-L-aspartate in human and murine cells in vitro.
Topics: Animals; Antineoplastic Agents; Aspartate Carbamoyltransferase; Aspartic Acid; Cell Division; Cell L | 1981 |
Pharmacological disposition of N-(phosphonacetyl)-L-aspartate in humans.
Topics: Aspartate Carbamoyltransferase; Aspartic Acid; Creatinine; Drug Evaluation; Humans; Metabolic Cleara | 1980 |
Quantitation of the antitumor agent N-(phosphonacetyl)-L-aspartic acid in human plasma and urine by gas chromatography-mass spectrometry-selected ion monitoring.
Topics: Antineoplastic Agents; Aspartic Acid; Gas Chromatography-Mass Spectrometry; Humans; Neoplasms; Organ | 1980 |
Phase I trial of PALA.
Topics: Antineoplastic Agents; Aspartic Acid; Brain Diseases; Diarrhea; Dose-Response Relationship, Drug; Ga | 1980 |
Specific aspartic acid-rich sequences are responsible for silver staining of nucleolar proteins.
Topics: Amino Acid Sequence; Aspartic Acid; Cell Nucleolus; Cloning, Molecular; Diagnosis, Differential; Esc | 1995 |
Loss of chromosomal integrity in neoplasia.
Topics: Animals; Aspartate Carbamoyltransferase; Aspartic Acid; Carbamoyl-Phosphate Synthase (Glutamine-Hydr | 1993 |
Photobleaching of mono-L-aspartyl chlorin e6 (NPe6): a candidate sensitizer for the photodynamic therapy of tumors.
Topics: Animals; Antineoplastic Agents; Aspartic Acid; Azides; Deuterium; Humans; Mannitol; Metronidazole; M | 1993 |
Uridine allows dose escalation of 5-fluorouracil when given with N-phosphonacetyl-L-aspartate, methotrexate, and leucovorin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Diarrhea; Drug Synergism | 1993 |
Presence of D-aspartate and D-glutamate in tumor proteins.
Topics: Aspartic Acid; Glutamic Acid; Humans; Neoplasm Proteins; Neoplasms; Stereoisomerism | 1995 |
Tumor, normal tissue, and plasma pharmacokinetic studies of fluorouracil biomodulation with N-phosphonacetyl-L-aspartate, folinic acid, and interferon alfa.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Area Under Curve; Aspartic Acid; Co | 1999 |
Tumor-enhancement effect of a Mn3+ metalloporphyrin derivative (ATN-4T) in magnetic resonance imaging.
Topics: Animals; Aspartic Acid; Carcinoma, Squamous Cell; Contrast Media; Deuteroporphyrins; Image Enhanceme | 1999 |
[Telomerases: transformation trial!].
Topics: Alanine; Antineoplastic Agents; Aspartic Acid; Catalytic Domain; Cell Division; DNA-Binding Proteins | 1999 |
Disruption of protein phosphatase 2A subunit interaction in human cancers with mutations in the A alpha subunit gene.
Topics: Amino Acid Sequence; Arginine; Aspartic Acid; Breast Neoplasms; Female; Glutamic Acid; Glycine; Huma | 2001 |
Isolation and identification of urinary beta-aspartyl dipeptides and their concentrations in human urine.
Topics: Adolescent; Adult; Aged; Aging; Aspartic Acid; Child; Dipeptides; Female; Glutamates; Glycine; Human | 1978 |
Phase I trial of N-(phosphonacetyl)-L-aspartate.
Topics: Adolescent; Adult; Aged; Aspartic Acid; Colonic Neoplasms; Diarrhea; Drug Eruptions; Drug Evaluation | 1979 |
The distribution and properties of aspartyl transfer RNA in human and animal tumors.
Topics: Adenocarcinoma; Animals; Aspartic Acid; Carcinoma; Carcinoma, Ehrlich Tumor; Cells, Cultured; Cricet | 1975 |
Phase I study of high dose 5-fluorouracil and high dose Leucovorin with low dose phosphonacetyl-L-aspartic acid in patients with advanced malignancies.
Topics: Adult; Aged; Antineoplastic Agents; Aspartic Acid; Drug Evaluation; Female; Fluorouracil; Humans; In | 1992 |
Phase I trial of PALA, methotrexate, fluorouracil, leucovorin, and uridine rescue in patients with advanced cancer. The use of uridine to decrease fluorouracil toxicity.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Aspart | 1990 |
The concentration of 5-phosphoribosyl 1-pyrophosphate in monolayer tumor cells and the effect of various pyrimidine antimetabolites.
Topics: Animals; Aspartic Acid; Cell Line; Cells, Cultured; Fluorouracil; Humans; Methotrexate; Neoplasms; O | 1985 |
Plasma uridine changes in cancer patients treated with the combination of dipyridamole and N-phosphonacetyl-L-aspartate.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Dipyridamole; Drug Evaluation; Female | 1986 |
Phase I trial of combination therapy of cancer with N-phosphonacetyl-L-aspartic acid and dipyridamole.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Dipyr | 1987 |
Aspartyl transfer RNA profiles in normal and cancer cells.
Topics: Animals; Ascites; Aspartic Acid; Breast Neoplasms; Carbon Isotopes; Carcinoma, Hepatocellular; Cell | 1972 |
[Urinary excretion of asparagne and aspartate in control subjects and patients with cancer before and after treatment with K-Mg-aspartate].
Topics: Adolescent; Adult; Aged; Asparagine; Aspartic Acid; Breast Neoplasms; Cholecystitis; Female; Humans; | 1972 |
Biochemical and pharmacological studies with asparaginase in man.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Asparaginase; Asparagine; Aspartic Acid; Child; Colo | 1970 |
Diminished oxidation of 14C-UL-L-asparagine to 14CO2 in mice and humans with tumors: a possible means for assessing efficacy of therapy?
Topics: Animals; Asparagine; Aspartic Acid; Carbon Dioxide; Carbon Isotopes; Humans; Injections, Intravenous | 1970 |
[Stimulation of the growth of neoplasms by administration of aspartic acid].
Topics: Asparaginase; Aspartic Acid; Neoplasms | 1970 |
[Change in the concentration of alpha-ketoglutaric acid in carcinoma patients by potassium-magnessium aspartate. 2].
Topics: Adult; Aged; Aspartic Acid; Female; Humans; Ketoglutaric Acids; Magnesium; Male; Methods; Middle Age | 1968 |